All In MedTech

Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed

FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

FDA decisions

1

De Novo pathway

Device trials

3

Naming "ShortCut"

MAUDE reports

0

Brand "ShortCut", since 2015

PubMed studies

2,318

Mentioning "ShortCut"

AI summary across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.

Product review deck

A slide deck reviewing ShortCut

About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.

  • Executive summary and key facts
  • Technology
  • Clinical evidence and trials
  • Regulatory history and safety
  • Reimbursement, market and competition
  • Risks, outlook and sources

AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.

FDA decisions

The newest 0 of 1 decisions filed under this name.

FDA's records could not be loaded.

Medicare coverage

National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.

How devices get paid for

Clinical trials

Device studies on ClinicalTrials.gov that name "ShortCut", any status and sponsor, newest update first.

Open in Trial Radar
  • Pi-cardiaNot on our public-company list

    NCT06211296 · 8 participants · Start Jul 3, 2024 · Primary completion May 12, 2025

    Device: Shortcut · For: Valve-in-valve Procedures; Aortic Stenosis; Coronary; Obstruction

    Sites: Thousand Oaks, California; Morristown, New Jersey; New York, New York · 4 sites in all

  • Pi-cardiaNot on our public-company list

    NCT07631988 · 150 participants (planned) · Start Jun 2026 · Primary completion Jul 2027

    Device: Transfemoral catheter designed to split the bioprosthetic aortic valve leaflets prior to TAVR · For: Aortic Stenosis Treated With TAVI

  • Pi-cardiaNot on our public-company list

    NCT04952909 · 60 participants · Start Jan 21, 2022 · Primary completion Sep 30, 2023

    Device: ShortCut™ · For: Risk of Coronary Obstruction Following Transcatheter Aortic Valve Replacement (TAVR) Procedure

    Sites: Tucson, Arizona; Los Angeles, California; San Francisco, California · 23 sites in all

Adverse event reports (MAUDE)

Reports received since 2015 naming the brand "ShortCut", and for the whole product code for context.

This brand

0 reports: 0 malfunction, 0 injury, 0 death

Whole product code SCZ

0 reports: 0 malfunction, 0 injury, 0 death

Newest reports for this brand

No MAUDE reports name this brand.

All reports in MAUDE Monitor

Recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

No recall in FDA's data is linked to these FDA numbers.

Published research

The most relevant PubMed records for "ShortCut"[tiab]. The summary above synthesizes these.

PubMedGoogle ScholarLiterature search

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.